European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation
Capri23auto / Pixabay

European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation

According to a press release from American biotechnology company Soligenix, the European Medicines Agency's (EMA) Pediatric Committee recently agreed to the Company’s Pediatric Investigation Plan (PIP) for experimental oral mucositis…

Continue Reading European Medicines Agency Okays Experimental Oral Mucositis Drug for Pediatric Investigation

New England Journal of Medicine (NEJM) Announces Results of A Unique Study of Hirschsprung Disease Affecting Infants

  An article in BioSpace reports new information published online by the NEJM concerning Hirschsprung disease. The disease involves the absence of nerves in parts of the intestines prior to birth. Researchers…

Continue Reading New England Journal of Medicine (NEJM) Announces Results of A Unique Study of Hirschsprung Disease Affecting Infants

Biomarker Identified Which Can Determine Severity of Idiopathic Pulmonary Fibrosis

Nigam Shah and Purvesh Khatri, professors at Stanford University, along with graduate student Madeleine Scott have just announced results from a research study which could be pivotal for those living…

Continue Reading Biomarker Identified Which Can Determine Severity of Idiopathic Pulmonary Fibrosis
The First Adeno-Associated Viral Gene Therapy for Huntington’s Disease Receives the FDA’s Fast Track Designation
mcmurryjulie / Pixabay

The First Adeno-Associated Viral Gene Therapy for Huntington’s Disease Receives the FDA’s Fast Track Designation

  A recent article in globenewswire.com news reported that the FDA has approved Fast Track Designation for AMT 130, an experimental gene therapy for the treatment of Huntington’s disease. The…

Continue Reading The First Adeno-Associated Viral Gene Therapy for Huntington’s Disease Receives the FDA’s Fast Track Designation
Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?
8385 / Pixabay

Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?

According to a story from BNN Bloomberg, gene therapies are without a doubt an upcoming advancement in care and treatment for many diseases that have a genetic origin. This includes…

Continue Reading Gene Therapy Could Change Rare Disease Treatment Forever, But Will Anyone be Able to Afford It?

Could a “Gene Expression Atlas” Unlock the Secrets of Amyotrophic Lateral Sclerosis?

According to a story from MD Magazine, the team at Spatial Transcriptomics has utilized an innovative computational approach in order to map gene expression on the spinal cords of patients…

Continue Reading Could a “Gene Expression Atlas” Unlock the Secrets of Amyotrophic Lateral Sclerosis?

Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

According to a story from Market Screener, the specialty pharmaceutical company Santhera Pharmaceuticals recently released an announcement in which the company revealed its intent to file for Conditional Marketing Authorization…

Continue Reading Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!

GT Biopharma has just announced that their Phase 1 clinical trial for Mastocytosis, Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML) has been authorized to begin. Although this investigation had previously…

Continue Reading New Phase 1 Clinical Trial for Mastocytosis, MDS, and AML has Just Begun!

New Potential Treatment for Neurofibromatosis Type 1 Given Breakthrough Therapy Designation

A new medication called selumetinib has just received Breakthrough Therapy designation by the FDA for pediatric patients diagnosed with neurofibromatosis type 1 (NF1) or inoperable pleciform neurofibromas. This therapy has…

Continue Reading New Potential Treatment for Neurofibromatosis Type 1 Given Breakthrough Therapy Designation